Login to Your Account

Other News To Note

Wednesday, August 24, 2011
• Cel-Sci Corp., of Vienna, Va., inked a sales, marketing and distribution agreement granting IDC-GP Pharm LLC an exclusive license to cancer therapy Multikine (leukocyte interleukin injection) in Argentina and Venezuela. IDC-GP is a joint venture between two pharmaceutical entrepreneurs with expertise in registration and commercialization in South America. Under the terms, IDC-GP will be responsible for seeking regulatory approval of Multikine and commercializing the drug in its territories, with revenues split 50-50 with Cel-Sci after payment for manufacturing costs. Specific terms were not disclosed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription